Document is current
Any future updates will be listed below
-
Authors
Sabino, Lorena Rodrigues https://orcid.org/0000-0002-5483-0419
Kaiko, Gerard E.
Dorahy, Douglas
Goodsall, Thomas
Jaffe, Adam
Schultz, Andre
Waters, Shafagh
Cook, Dane
Kok, Harvey
Tong, Koliarne
Totterdell, James
McGree, James
Snelling, Tom
Wark, Peter A. B.
-
Funding
Funding for this research was provided by:
MRFF Australia
- License Information
-
More Information
Article History
Received: 14 October 2025
Accepted: 10 May 2026
First Online: 15 June 2026
Declarations
Ethics approval and consent to participate {24}: This study has been approved by the Hunter New England Human Research Ethics Committee, registration number 2023/STE01015 on May 16th 2023. Written informed consent is obtained from all participants.
Consent for publication {32}: Not applicable. No identifying images or other personal or identifiable clinical information of participants are presented here or will be presented in reports of the trial results.
Competing interests {28}: GK has a patent on an RNA therapy for CFTR, and shareholding in Akte Therapeutics a gene therapy company. TMG has received speaker fees and research support from Johnson & Johnson and speaker and advisory fees from Abbvie.The other authors declare that they have no competing interests.
